The miniNO project consortium successfully held its Final Annual Meeting on December 8–9, 2025 in Lille, bringing together partners from across Europe in a hybrid format.
The meeting gathered more than 20 participants from leading institutions, including Inserm, University of Geneva, National and Kapodistrian University of Athens, Queen Mary University of London, Centre Hospitalier Universitaire Vaudois, Université de Lille, Centre Hospitalier Universitaire de Lille, and University Hospital Würzburg as well as Alithea Genomics.
The main objective was to review progress across all work packages and align on the next steps toward the final phase of the project. Discussions covered key topics such as nitric oxide-based therapies, early-life development, genetic and epigenetic factors of prematurity, and advances in data analysis and biomarker discovery.
The meeting highlighted significant progress, confirming the potential of nitric oxide-related approaches in improving outcomes for babies born too soon, while also emphasizing the importance of multidisciplinary collaboration and data integration.
As the project moves forward, partners will focus on final analyses, publications, and actively sharing results with healthcare professionals, parents, and the wider public to maximize real-world impact.
